Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

0301 basic medicine Cell Death Dose-Response Relationship, Drug Cell Survival Pyridines Imidazoles Mice, Nude HCT116 Cells Heterocyclic Compounds, 4 or More Rings Xenograft Model Antitumor Assays 3. Good health Killer Cells, Natural TNF-Related Apoptosis-Inducing Ligand Mice 03 medical and health sciences Pyrimidines Animals Humans Female Neoplasm Metastasis Colorectal Neoplasms Cell Proliferation Signal Transduction
DOI: 10.1172/jci96711 Publication Date: 2018-03-20T20:43:16Z
ABSTRACT
ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. has demonstrated safety and preliminary efficacy first-in-human trial which patients were dosed every 3 weeks. We hypothesized dose intensification of may impact efficacy. discovered exerts dose- schedule-dependent effects on tumor progression cell death vivo. With intensification, we note potent anti-metastasis effect inhibition migration invasion. Our preclinical results prompted change dosing all open clinical trials. observed accumulation activated NK+ CD3+ cells within ONC201-treated tumors NK depletion inhibits vivo, including against TRAIL/ONC201-resistant Bax–/– tumors. Immunocompetent NCR1-GFP mice, express GFP, GFP+ infiltration syngeneic MC38 colorectal Activation primary human increased degranulation occurred response to ONC201. Coculture experiments identified role for NK-mediated cytotoxicity. Preclinical indicate the potential utility plus anti–PD-1 therapy. an increase TRAIL-secreting peripheral blood after treatment. The offer what believe be unique immune stimulation
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (34)
CITATIONS (62)